Sunitinib
- PDF / 183,752 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 106 Downloads / 163 Views
1
★
Hair depigmentation (first report) in a patient with an acquired c-KIT mutation: case report A 47-year-old man with a supposed diagnosis of high-risk GI stromal tumour, and an acquired stem cell factor receptor (cKIT) mutation, developed periodic hair depigmentation during treatment with sunitinib [Sutent]. The man, who had previously received imatinib, started receiving oral sunitinib 50 mg/day for 4 weeks, followed by 2 weeks without treatment. During 5 months of treatment, his skin, head hair and beard hair became progressively discoloured [time to onset not clearly stated]. His beard hair had alternating coloured and uncoloured parts, and the uncoloured part was longer than the coloured part. The growth of the uncoloured portion of his hair corresponded to the 4 weeks when he was receiving sunitinib, and the growth of pigmented hair corresponded to the 2 weeks when he was not receiving the drug. The authors presented a figure of the patient’s beard hair showing alternating coloured and uncoloured portions representing 3.5 cycles of sunitinib treatment. [Patient outcome not stated.] Author comment: "[W]e propose a correlation between temporary inhibition of c-KIT throughout sunitinib treatment: the periodic change mimics the sunitinib treatment schedule." Hartmann JT, et al. Sunitinib and periodic hair depigmentation due to temporary cKIT inhibition. Archives of Dermatology 144: 1525-1526, No. 11, Nov 2008 801118778 Germany
» Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of hair depigmentation associated with sunitinib. The WHO Adverse Drug Reactions database contained four reports of hair discolouration associated with sunitinib.
0114-9954/10/1230-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 29 Nov 2008 No. 1230
Data Loading...
